{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(9)"],"submitter":["Webster LR"],"pubmed_abstract":["Objective
To compare the relative human abuse potential after insufflation of manipulated morphine abuse-deterrent, extended-release injection-molded tablets (morphine-ADER-IMT) with that of marketed morphine ER tablets.Methods
A randomized, double-blind, double-dummy, active- and placebo-controlled five-way crossover study was performed with adult volunteers who were experienced, nondependent, recreational opioid users. After intranasal (IN) administration of manipulated high-volume (HV) morphine-ADER-IMT (60 mg), participants were randomized (1:1:1:1) to receive IN manipulated low-volume (LV) morphine ER (60 mg), IN manipulated LV morphine-ADER-IMT, intact oral morphine-ADER-IMT (60 mg), and placebo in crossover fashion. Pharmacodynamic and pharmacokinetic assessments inc"],"journal":["Pain medicine (Malden, Mass.)"],"pagination":["1695-1705"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5939830"],"repository":["biostudies-literature"],"pubmed_title":["Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users."],"pmcid":["PMC5939830"],"pubmed_authors":["Dayno JM","Lindhardt K","Lawler J","Smith MD","Webster LR"],"additional_accession":[]},"is_claimable":false,"name":"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.","description":"Objective
To compare the relative human abuse potential after insufflation of manipulated morphine abuse-deterrent, extended-release injection-molded tablets (morphine-ADER-IMT) with that of marketed morphine ER tablets.Methods
A randomized, double-blind, double-dummy, active- and placebo-controlled five-way crossover study was performed with adult volunteers who were experienced, nondependent, recreational opioid users. After intranasal (IN) administration of manipulated high-volume (HV) morphine-ADER-IMT (60 mg), participants were randomized (1:1:1:1) to receive IN manipulated low-volume (LV) morphine ER (60 mg), IN manipulated LV morphine-ADER-IMT, intact oral morphine-ADER-IMT (60 mg), and placebo in crossover fashion. Pharmacodynamic and pharmacokinetic assessments inc","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Sep","modification":"2025-04-22T01:39:42.85Z","creation":"2019-03-26T23:37:13Z"},"accession":"S-EPMC5939830","cross_references":{"pubmed":["27651510"],"doi":["10.1093/pm/pnw219"]}}